Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Amortization of Deferred Charges: 2020-2023

Historic Amortization of Deferred Charges for Journey Medical (DERM) over the last 3 years, with Sep 2023 value amounting to $177,000.

  • Journey Medical's Amortization of Deferred Charges fell 11.94% to $177,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $504,000, marking a year-over-year decrease of 35.71%. This contributed to the annual value of $353,000 for FY2023, which is 54.16% down from last year.
  • Latest data reveals that Journey Medical reported Amortization of Deferred Charges of $177,000 as of Q3 2023, which was up 126.92% from $78,000 recorded in Q2 2023.
  • In the past 5 years, Journey Medical's Amortization of Deferred Charges ranged from a high of $804,000 in Q2 2021 and a low of -$409,000 during Q3 2021.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $177,000 (2023), whereas its average is $173,091.
  • The largest annual percentage gain for Journey Medical's Amortization of Deferred Charges in the last 5 years was 149.14% (2022), contrasted with its biggest fall of 73.26% (2022).
  • Over the past 4 years, Journey Medical's Amortization of Deferred Charges (Quarterly) stood at $206,000 in 2020, then decreased by 19.90% to $165,000 in 2021, then decreased by 8.48% to $151,000 in 2022, then fell by 11.94% to $177,000 in 2023.
  • Its Amortization of Deferred Charges was $177,000 in Q3 2023, compared to $78,000 in Q2 2023 and $98,000 in Q1 2023.